Evidence map›Paper›PMID 39834829›Full record

ReviewFrontiers in pharmacology2024

Bergenin, a bioactive flavonoid: advancements in the prospects of anticancer mechanism, pharmacokinetics and nanoformulations.

Pratibha Pandey, Sorabh Lakhanpal, Danish Mahmood, Han Na Kang, Byunggyu Kim, Sojin Kang, Jinwon Choi, Seungjoon Moon, Shivam Pandey, Suhas Ballal and 3 more

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Unveiling the Cytotoxicity Potential of Nanoemulsion ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Pratibha PandeyCentre for Research Impact and Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, India.
Sorabh LakhanpalSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India.
Danish MahmoodDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Saudi Arabia.
Han Na KangKM Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.
Byunggyu KimDepartment of Pathology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
Sojin KangDepartment of Pathology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
Jinwon ChoiDepartment of Pathology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
Seungjoon MoonDepartment of Pathology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
Shivam PandeySchool of Applied and Life Sciences, Uttaranchal University, Dehradun, India.
Suhas BallalDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, India.
Sanjay KumarDepartment of Allied Healthcare and Sciences, Vivekananda Global University, Rajasthan, India.
Fahad KhanCenter for Global Health Research Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Chennai, India.
Bonglee KimDepartment of Pathology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The natural world is a vast reservoir of exceptionally varied and inventive chemical compositions. Natural products are used as initial compounds to create combinatorial libraries by targeted modifications and then by analyzing their structure-activity connections. This stage is regarded as a crucial milestone in drug discovery and development. Bergenin, a naturally occurring secondary metabolite, has been extracted from several plant components. It is a constituent found in herbal and Ayurvedic preparations. It demonstrates antiviral, antifungal, antitussive, antiplasmodial, anti-inflammatory, antihepatotoxic, antiarrhythmic, antitumor, antiulcerogenic, antidiabetic, and wound healing activities. Bergenin efficiently inhibited the proliferation of human cancer cells by stimulating the production of intracellular reactive oxygen species (ROS), causing DNA damage and leading to cell cycle arrest in the G1/G2 phases by blocking cell signaling pathways. More comprehensive reviews are needed on the anticancer properties of bergenin. Therefore, our review aimed to update the multifaceted benefits of bergenin to the future scientists and researchers, which can be leveraged to formulate safer and novel cancer therapies, while also establishing a robust framework for future investigations into bergenin in cancer treatment. More preclinical and clinical investigations are needed to validate the candidature of bergenin as a potent anticancer agent.

Indexed as

anticancerbergenincancerpharmacokinetictherapeutics

Identifiers

PMID39834829
PMCPMC11743450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.